http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Accuray Announces Approval of the Accuray Precision® Treatment Planning System by China's National Medical Products Administration
-
Accuray to Participate in the 14th Annual Jefferies London Healthcare Conference
-
Accuray to Report First Quarter Fiscal 2024 Financial Results on November 7, 2023
-
Accuray (ARAY) Announces Approval of the Tomo C Radiation Treatment Delivery System in China
-
Accuray Announces Approval of the Tomo® C Radiation Treatment Delivery System by China's National Medical Products Administration
-
Accuray and Limbus AI Unveil Online Adaptive Therapy Solution for the Radixact® System at American Society for Radiation Oncology (ASTRO) Annual Meeting
-
Accuray Opens New Global Training Center at Madison, WI Headquarters to Advance Radiotherapy Treatment Techniques Amid Growing Demand for Precision Cancer Care
-
Accuray to Host Investor Day at ASTRO on October 3, 2023
-
Accuray Receives FDA Clearance for VitalHold™ on the Radixact® System; Breast Cancer Treatment Option Will Also Be Available in the EU Market
-
Accuray to Report Fiscal Year-End 2023 Financial Results on August 9, 2023
-
Accuray (ARAY) Announces Its Addition to the Russell 2000 Index
-
Accuray Incorporated Announces Its Addition to the Russell 2000® Index
-
Accuray Announces Suzanne Winter Selected as One of the Top 50 Healthcare Technology CEOs of 2023
-
Accuray CyberKnife® and TomoTherapy® Platforms Featured in More Than 55 Abstracts Presented at ESTRO 2023, Reinforcing Systems' Versatility, Efficiency and Effectiveness
-
Accuray to Report Third Quarter Fiscal 2023 Financial Results on April 26, 2023
-
Accuray Incorporated to Speak at 33rd Annual Oppenheimer Healthcare Conference
-
Accuray to Participate in the Cowen 43rd Annual Health Care Conference
-
Trial Data Indicates Targeted, Short Course Radiation Therapy Preserves Urinary Continence and Sexual Function Better Than Surgery in Men With Prostate Cancer
-
Accuray to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
-
Accuray (ARAY) Appoints Robert C. Kill to its Board
-
Robert C. Kill Joins Accuray Board of Directors
-
European Radiosurgery Center Munich Invests in Second Accuray CyberKnife® System to Support the Demand for High-Precision Radiosurgery Treatments
-
Accuray to Report Second Quarter Fiscal 2023 Financial Results on February 1, 2023
-
Accuray Announces First Patient Treatments in New Zealand With the CyberKnife® System, the World's Only Robotic Radiation Therapy Delivery Device
-
Accuray Receives IMV Award for Best In Service in Radiation Oncology for 2022
-
Oscar Lambret Center in France Installs Second Accuray Radixact® System, the Hospital's Fifth Accuray Radiation Therapy Delivery System
-
Accuray (ARAY) Announces Tomo C Registration Submission to China's National Medical Products Administration
-
Accuray Announces Tomo® C Registration Submission to China's National Medical Products Administration
-
Accuray (ARAY) Announces Accuray CyberKnife System Approved for Reimbursement in Japan
-
New Reimbursement Approved by the Japanese Ministry of Health, Labor and Welfare for the Accuray CyberKnife® System to Treat Trigeminal Neuralgia, a Condition Often Causing Severe Facial Pain
-
GE Healthcare and Accuray Collaborate to Expand Access, Advance the Practice of Precision Radiation Therapy
-
Accuray to Report First Quarter Fiscal 2023 Financial Results on November 2, 2022
-
Accuray and C-RAD Unveil Automated Breast Cancer Treatment Package for the Radixact® System at American Society for Radiation Oncology (ASTRO) Annual Meeting
-
Accuray (ARAY) Reports Publication Showing Men With Prostate Cancer Treated With the Accuray CyberKnife Platform Experienced a Lower Incidence of Bladder Side Effects
-
Data Published in The Lancet Oncology Indicate Men With Prostate Cancer Treated With the Accuray CyberKnife® Platform Experienced a Lower Incidence of Bladder Side Effects Than Those Treated With Con
-
Accuray to Host Meeting with Analysts and Investors at ASTRO on October 24, 2022
-
Accuray Announces First CyberKnife® Systems in Africa, Providing a New Option and Hope for Potentially Life-Saving Radiation Treatments for More Cancer Patients
-
Dr. Seth Blacksburg Joins Accuray as VP, Chief Medical Officer Americas Region
-
Accuray Partners with Swiss-based Genolier Innovation Hub to Bring Medical and Technological Advances to Patients Faster
-
Accuray to Report Fiscal Year-End 2022 Financial Results on August 10, 2022
-
Accuray CyberKnife® System Real World Data and Clinical Studies Show Benefits in Treatment of Neurological Indications
-
Accuray Appoints Franco N. Palomba as VP, Chief Accounting Officer & Controller
-
Accuray Incorporated Reports Inducement Awards Under NASDAQ Listing Rules
-
Accuray and Limbus AI Inc. Partner to Leverage Limbus' Innovative AI-driven Technology to Enhance Accuray Adaptive Radiotherapy Solutions
-
Accuray (ARAY) Appoints Sandeep Chalke as Chief Commercial Officer
-
Accuray Appoints Sandeep Chalke as SVP, Chief Commercial Officer
-
New Data Presented at ESTRO 2022 Reinforce Benefits of Accuray CyberKnife® and TomoTherapy® Platforms Across a Range of Indications and Complexities
-
Accuray ClearRT™ Helical Fan-Beam kVCT Imaging Wins "Best New Technology Solution for Oncology" MedTech Breakthrough Award
-
Accuray (ARAY) Announces Suzanne Winter, President, Promoted to President and CEO; Joshua Levine Will Retire as CEO and Board Member
-
Accuray Announces Suzanne Winter, President, Promoted to President and CEO; Joshua Levine Will Retire as CEO and Board Member
